PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals — Investor Presentation (November 2020)

28 slides from PhaseBio Pharmaceuticals's investor presentation, Nov 12, 2020

  1. Slide 1: Corporate Overview November 2020

    Corporate Overview November 2020

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”)

  3. Slide 3: Company Overview

    Company Overview Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat cardiopulmonary Therapeutic Focus diseases Bentracimab Novel agent in Phase 3 development for immediate and sustained reversal of ticagrelor, the preferred antiplatelet (PB2

  4. Slide 4: A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company

    A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone Bentracimab REVERSE-IT1 Phase 3 ongoing 2H 2020 Reversal of Ticagrelor Targeting to submit BLA in 2H222 Target for publication of Antiplatelet Activit

  5. Slide 5: Corporate

    ) Corporate

  6. Slide 6: Creating Value for Stakeholders in 2020

    Creating Value for Stakeholders in 2020 • Following a successful 2019, PhaseBio continues a rapid pace of development and execution in 2020  Announced innovative funding and co-development collaboration for bentracimab with SFJ Pharmaceuticals  Bolstered pipeline with acquisition of resistant hype

  7. Slide 7: Third-Quarter 2020 Financial Highlights

    Third-Quarter 2020 Financial Highlights • Operating expense: $20.5M ⎯ R&D: $17.4M ⎯ SG&A: $3.1M • Loss from Operations: ($20.5M) • Net Loss of ($25.1M) or ($0.86) per share ⎯ 29.2M shares used for computing Q3 2020 net loss per share • Cash and cash equivalents as of 09/30/2020: $39.4M 7

  8. Slide 8: Experienced Management Team

    Experienced Management Team JONATHAN MOW SUSAN ARNOLD, PhD JIM BALLANCE, PhD GLEN BURKHARDT Chief Executive Officer VP of Preclinical & CMC VP Research & Scientific Affairs VP Human Resources KRIS HANSON JOHN LEE, MD, JOHN SHARP MICHAEL YORK VP Legal PhD, FACC Chief Financial Officer VP Corp Develop

  9. Slide 9: (PB2452) Reversal Agent for Ticagrelor

    Bentracimab (PB2452) Reversal Agent for Ticagrelor

  10. Slide 10: Bentracimab: Novel Reversal Agent for Brilinta (Ticagrelor)

    Bentracimab Bentracimab: Novel Reversal Agent for Brilinta (Ticagrelor) • Within the P2Y12 antagonist class of oral antiplatelet therapies, ticagrelor has proven superiority vs. clopidogrel, and a unique reversible binding profile ⎯ Clopidogrel and prasugrel, the other members of the oral P2Y12 anta

  11. Slide 11: Bentracimab: Well-Characterized Mechanism of Reversal of Ticagrelor

    Bentracimab Bentracimab: Well-Characterized Mechanism of Reversal of Ticagrelor 1. ADP binds to P2Y12 3. Bentracimab binds to free 5. As free ticagrelor is eliminated, ADP can again receptor causing ticagrelor with very high affinity activate the P2Y12 receptor, restoring platelet platelet aggregati

  12. Slide 12: Bentracimab: Development and Regulatory Timelines

    Bentracimab Bentracimab: Development and Regulatory Timelines* 2019 2020 2021 2022 2023 NEJM Phase 2a Phase 2b: Older and elderly subjects N=200, 150 randomized to receive bentracimab Breakthrough FDA EMA PRIME Phase 3 interim analysis for Accelerated Approval Post-approval completion of Phase 3 The

  13. Slide 13: Bentracimab Phase 1 Proof-of-Concept Study in Healthy Subjects

    Bentracimab Bentracimab Phase 1 Proof-of-Concept Study in Healthy Subjects • Randomized, double-blind, placebo-controlled, single ascending dose, sequential group study (n=64) • Platelet function evaluated using three well established and commonly used assays: LTA, VerifyNow PRUTest® and VASP ⎯ Resu

  14. Slide 14: Normalized Platelet Function After Ticagrelor Reversal

    Bentracimab Normalized Platelet Function After Ticagrelor Reversal VerifyNow PRUTest Return to Normal Platelet Normal Platelet Function: Inhibited Platelet Function: Function: Post-Bentracimab Pre-Ticagrelor Dosing Post-Ticagrelor Dosing Dosing Normal Platelet Function Inhibited Platelet Function Pl

  15. Slide 15: Positive Preliminary Bentracimab Phase 2a Results

    Bentracimab Positive Preliminary Bentracimab Phase 2a Results • Positive preliminary results from the bentracimab Phase 2a trial were disclosed via press release1 ⎯ First trial of bentracimab to include older and elderly subjects (ages 50-80) on dual antiplatelet therapy (DAPT) of ticagrelor and low

  16. Slide 16: REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview

    Bentracimab REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview • REVERSE-IT: Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial • Phase 3 trial is a key element of development plan that has garnered FDA Breakthrough Therapy and EMA PRIME designations • Open-label, single-arm study o

  17. Slide 17: Bentracimab Regulatory Updates

    Bentracimab Bentracimab Regulatory Updates Development plan for bentracimab designed with objective to broadly support global regulatory filings Separate written guidance from FDA and EMA indicates that REVERSE-IT, a single, non-randomized, open-label Phase 3 trial of bentracimab in both surgical an

  18. Slide 18: SFJ Pharmaceuticals Funding and Co-Development Collaboration

    Bentracimab SFJ Pharmaceuticals Funding and Co-Development Collaboration • Innovative collaboration between SFJ and PhaseBio to support the global development of bentracimab • SFJ will fund up to $120 million to support the clinical development of bentracimab ⎯ SFJ has extensive experience in the gl

  19. Slide 19: Expect Continued Long-Term Rx Growth of Ticagrelor

    Bentracimab Expect Continued Long-Term Rx Growth of Ticagrelor Bentracimab approval has the potential to drive continued positive momentum • Brilinta/Brilique sales in 2019 were $1.58B and growing (+20% Y/Y) ⎯ Patient growth drives Y/Y revenue growth in key regions: strong growth in the United State

  20. Slide 20: Pemziviptadil (PB1046) Once Weekly Vasoactive Intestinal Peptide (VIP) Analog

    Pemziviptadil (PB1046) Once Weekly Vasoactive Intestinal Peptide (VIP) Analog

  21. Slide 21: Pemziviptadil: Harnessing VIP to Create a Stable, Long-Acting Drug

    Pemziviptadil Pemziviptadil: Harnessing VIP to Create a Stable, Long-Acting Drug VIP as a THERAPEUTIC AGENT PRECLINICAL STUDIES Endogenous VIP Pemziviptadil Support Clinical Development for: • Pulmonary Arterial Hypertension • DMD Cardiomyopathy • Heart Failure (Chemotherapy-Induced HF or HFpEF) • C

  22. Slide 22: Proprietary Elastin-Like Polypeptide (ELP) Technology

    Pemziviptadil Proprietary Elastin-Like Polypeptide (ELP) Technology Key to optimizing the profile of an injectable VIP product candidate PROLONGED CIRCULATING HALF-LIFE COACERVATION DELIVERS SLOW RELEASE “Biopolymer” Repeating Sequence of Human Elastin Peptides Outside Body Inside Body Active Moiety

  23. Slide 23: High Unmet Need in an Orphan Disease

    Pemziviptadil High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) • High unmet need for novel disease-modifying PAH therapies for greater efficacy ⎯ All 3 approved drug classes in PAH are vasodilators: prostacyclin, endothelin, and nitric oxide pathways

  24. Slide 24: Pemziviptadil Clinical Development Activities to Date

    Pemziviptadil Pemziviptadil Clinical Development Activities to Date Have Supported Advancement into Phase 2 Efficacy Studies PHASE 1 Studies Completed PHASE 2 PAH Studies SAD study in Open-Label Phase 2a CardioMEMS Phase 2b PAH Efficacy hypertensive patients 4-week MAD study in in PAH study: Safety

  25. Slide 25: PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension

    PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension

  26. Slide 26: PB6440 for Resistant Hypertension

    PB6440 PB6440 for Resistant Hypertension • Upwards of 10 million patients in the United States have resistant hypertension and are at risk for serious, costly medical consequences (stroke, heart attack, kidney failure, etc.)1 • Physicians currently prescribe numerous combinations of antihypertensive

  27. Slide 27: PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2)

    PB6440 PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2) Selectivity and Potency Demonstrated in Primate Chronic Oral Dosing Model CYP11B Potency and Selectivity (IC50, µM) Human Monkey CYP11B2 CYP11B1# Selectivity CYP11B2 CYP11B1 Selectivity PB6440 0.024 4.859 202 0.016 5.802 363 LCI699

  28. Slide 28: PhaseBio

    PhaseBio

PhaseBio Pharmaceuticals — Investor Presentation (November 2020) on 6ix